STA, 30 July 2020 – The group around the drug maker Krka generated EUR 803.8 million in sales revenue in the first half of the year, a 6% increase compared to the same period in 2019, while gaining EUR 160.3 million in net profit, up 15% year-on-year, the company said in a press release on Thursday.
After the half-year report was discussed by the Krka supervisory board on Wednesday, the management issued a statement today saying that "the Krka Group performed well in the first half of the business year, and reached record results."
"Despite the coronavirus pandemic outbreak, Krka has kept the supply of medicinal products to markets across the world uninterrupted," said CEO Jože Colarič.
The release adds that the Novo Mesto-based group entered the second half of the year in a sound financial condition, and the plan for the entire 2020 is to generate operating income of EUR 1.52 billion, and to increase net profit to EUR 210 million.
"Development of the coronavirus situation, spreading of the disease, its aftermaths, and the related measures of the affected nations are highly uncertain. We are therefore closely monitoring the situation and adapting accordingly in countries where we operate."
